Clinical trials targeting immune checkpoint molecules such as PD-1 for the treatment of TGCT mainly failed, probably due to our incomplete understanding of the TGCT immune microenvironment [36, 49, 54], but IL-6 has been considered as a potential immunotherapeutic target in seminoma [8, 22]. This evidence concerns the gene IL6 and testicular germ cell tumor.